Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT

Exclusion Criteria

• •1. GVHD (graft versus host disease) ≥ grade Ⅱ；
• •2. Thrombotic microangiopathy；
• •3. Posttransplant lymphoproliferative disorders；
• •4. Uncontrolled infection or other uncontrolled medical or psychiatric disorders which may preclude patients to undergo clinical studies (discretion of the attending physician)；
• •5. Patients with chronic diseases that require treatment with immune agents or hormones;
• •6. Suffering from systemic autoimmune disease or immunodeficiency disease;
• •7. Systemic use of steroids;
• •8. Allergic constitution;
• •9. Hemorrhagic disease or coagulation disorders;
• •10. Patients participating in other clinical trials within 30 days prior to enrollment;
• •11. Patients receiving radiotherapy within 4 weeks prior to enrollment;
• •12. Pregnant or breastfeeding women;
• •13. According to the researcher's judgment, the patient has other unsuitable conditions.